Neurodegenerative Disease Market

Executive Summary

Neurodegenerative Disease Market was valued at US $46.94 billion in 2021 and is projected to grow at 7.41% CAGR over the forecast period to reach US $72.09 billion by 2027. Neurodegenerative Disease Market represented US $6.25 billion opportunity over 2019-2021 and estimated to create US $25.15 billion opportunity in 2027 over 2021.

Neurodegenerative Disease from Consainsights analyses the Neurodegenerative Disease Market in the Life Sciences industry over the forecast period to 2027.

Neurodegenerative Disease research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Neurodegenerative Disease segmentation includes Indication Type, Drug Type and Geography.

Based on the Indication Type, the Neurodegenerative Disease analysis covers Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types.

In Indication Type segment, Parkinson's Disease segment has highest cagr growth of 6.56%.

Based on the Drug Type, the Neurodegenerative Disease analysis covers N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Other Drug Types.

In Drug Type segment, N-methyl-D-aspartate Receptor antagonists segment has highest cagr growth of 6.56%.

Based on the region, the Neurodegenerative Disease analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include AbbVie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical, UCB SA, Biogen Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Indication Type

Introduction

In 2021, Parkinson's Disease segment has the highest revenue of US $17.74 billion and is expected to grow at CAGR of 6.56% by 2027 Parkinson's Disease segment has highest cagr growth of 6.56%.

Parkinson's Disease

Parkinson's Disease segment was valued at US $15.38 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $27.24 billion by 2027. Parkinson's Disease segment represented US $2.36 billion opportunity over 2019-2021 and estimated to create US $9.50 billion opportunity in 2027 over 2021.

Alzheimer's Disease

Alzheimer's Disease segment was valued at US $12.04 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $21.33 billion by 2027. Alzheimer's Disease segment represented US $1.85 billion opportunity over 2019-2021 and estimated to create US $7.44 billion opportunity in 2027 over 2021.

Multiple Sclerosis

Multiple Sclerosis segment was valued at US $5.56 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $9.85 billion by 2027. Multiple Sclerosis segment represented US $0.85 billion opportunity over 2019-2021 and estimated to create US $3.43 billion opportunity in 2027 over 2021.

Huntington Disease

Huntington Disease segment was valued at US $6.12 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $10.84 billion by 2027. Huntington Disease segment represented US $0.94 billion opportunity over 2019-2021 and estimated to create US $3.78 billion opportunity in 2027 over 2021.

Other Indication Types

Other Indication Types segment was valued at US $1.60 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $2.83 billion by 2027. Other Indication Types segment represented US $0.25 billion opportunity over 2019-2021 and estimated to create US $0.99 billion opportunity in 2027 over 2021.

Drug Type

Introduction

In 2021, N-methyl-D-aspartate Receptor antagonists segment has the highest revenue of US $18.93 billion and is expected to grow at CAGR of 6.56% by 2027 N-methyl-D-aspartate Receptor antagonists segment has highest cagr growth of 6.56%.

N-methyl-D-aspartate Receptor antagonists

N-methyl-D-aspartate Receptor antagonists segment was valued at US $16.41 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $29.07 billion by 2027. N-methyl-D-aspartate Receptor antagonists segment represented US $2.52 billion opportunity over 2019-2021 and estimated to create US $10.14 billion opportunity in 2027 over 2021.

Cholinesterase Inhibitors

Cholinesterase Inhibitors segment was valued at US $13.22 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $23.43 billion by 2027. Cholinesterase Inhibitors segment represented US $2.03 billion opportunity over 2019-2021 and estimated to create US $8.17 billion opportunity in 2027 over 2021.

Dopamine Agonists

Dopamine Agonists segment was valued at US $4.64 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $8.22 billion by 2027. Dopamine Agonists segment represented US $0.71 billion opportunity over 2019-2021 and estimated to create US $2.87 billion opportunity in 2027 over 2021.

Immunomodulatory Drugs

Immunomodulatory Drugs segment was valued at US $2.54 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $4.50 billion by 2027. Immunomodulatory Drugs segment represented US $0.39 billion opportunity over 2019-2021 and estimated to create US $1.57 billion opportunity in 2027 over 2021.

Other Drug Types

Other Drug Types segment was valued at US $3.87 billion in 2019 and is projected to grow at 6.56% CAGR over the forecast period to reach US $6.85 billion by 2027. Other Drug Types segment represented US $0.59 billion opportunity over 2019-2021 and estimated to create US $2.39 billion opportunity in 2027 over 2021.